The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Anakinra Market Over The 2026–2030 Period?
The anakinra market has observed substantial growth in recent years. It is anticipated to increase from $5.46 billion in 2025 to $6.12 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.1%. This historical expansion can be linked to the rising prevalence of rheumatoid arthritis, increased adoption of biologics, the expansion of specialty clinics, enhanced diagnosis of rare diseases, and augmented immunology research.
The market for anakinra is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $9.61 billion, driven by a compound annual growth rate (CAGR) of 11.9%. This projected increase during the forecast timeframe stems from several factors, including the development of biologic therapies, a rise in rare disease diagnoses, the broadening of homecare environments, a greater number of immunology trials, and enhanced access to healthcare. Significant tendencies expected during this period involve the increasing application of biologic anti-inflammatory treatments, wider acceptance for rare autoinflammatory conditions, a heightened emphasis on managing diseases for extended durations, the proliferation of home-administered injection treatments, and a greater prevalence of its use for off-label inflammatory ailments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp
What Underlying Factors Are Accelerating The Growth Of The Anakinra Market?
The escalating prevalence of autoimmune disorders is anticipated to stimulate the expansion of the anakinra market moving forward. These conditions arise when the body’s immune system mistakenly attacks and damages its own healthy tissues and organs, perceiving them as foreign invaders. The growing incidence of autoimmune disorders stems from a combination of genetic susceptibility and environmental factors, including infections, pollution, and dietary shifts, all contributing to their increased occurrence. Anakinra functions by blocking interleukin-1 (IL-1) activity to treat autoimmune disorders, thereby mitigating inflammation in conditions like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, in February 2025, the Australian Broadcasting Corporation, an Australia-based national public broadcaster, stated that inflammatory bowel disease currently affects almost 180,000 Australians, with Crohn’s Disease impacting 93,700 and Ulcerative Colitis affecting 80,430 individuals, and this total number is expected to climb to 200,000 in the next 10 years. Hence, the increasing occurrence of autoimmune disorders is propelling the growth of the anakinra market.
How Is The Anakinra Market Segmented Across Key Categories?
The anakinra market covered in this report is segmented –
1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Spondyloarthritis
Who Are The Dominant Players Shaping The Anakinra Market Landscape?
Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.
Read the full anakinra market report here:
https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report
Which Region Is Projected To Dominate The Anakinra Market During The Forecast Period?
North America was the largest region in the anakinra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anakinra Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp
Browse Through More Reports Similar to the Global Anakinra Market 2026, By The Business Research Company
Anthracycline Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report
Chemotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Sukuk Market Report 2026
https://www.thebusinessresearchcompany.com/report/sukuk-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model